# A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

> **NCT05418868** · PHASE1 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 214 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir 200 mg/mL
- **DRUG:** Cabotegravir >=400 mg/mL
- **DRUG:** Cabotegravir Formulation I
- **DRUG:** CAB Formulation J
- **DRUG:** rHuPH20
- **DRUG:** RPV

## Key facts

- **NCT ID:** NCT05418868
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-14
- **Primary completion:** 2027-06-08
- **Final completion:** 2027-06-08
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05418868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05418868, "A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05418868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*